MINI-FOCUS: INFLAMMATION IN CARDIAC INJURY The IL-1b Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure
Résumé
HIGHLIGHTS Immediate IL-1b antibody gevokizumab administration reduces ischemia/ reperfusion related infarct size. Immediate and late IL-1b antibody gevokizumab administration improves heart failure related left ventricular remodeling. IL-1b antibody gevokizumab improves heart failure related coronary dysfunction. From
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Loading...